Nabriva Drug Patent Portfolio
Nabriva owns 1 orange book drug protected by 4 US patents Given below is the list of Nabriva's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9120727 | Process for the preparation of pleuromutilins | 23 May, 2031 | Active |
| US8071643 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | 16 Jan, 2029 | Active |
| US8153689 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | 19 Mar, 2028 | Active |
| US6753445 | Pleuromutilin derivatives having antibacterial activity | 09 Jul, 2021 | Expired |
Latest Legal Activities on Nabriva's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nabriva.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 02 Oct, 2023 | US8153689 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 23 May, 2023 | US8071643 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 22 Feb, 2023 | US9120727 |
|
Patent Term Extension Certificate
Critical
| 15 Feb, 2023 | US8071643 |
|
Withdrawal of Application for PTE
Critical
| 14 Feb, 2023 | US8153689 |
|
Withdrawal of Application for PTE
Critical
| 14 Feb, 2023 | US9120727 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US9120727 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8153689 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8071643 |
| transaction for FDA Determination of Regulatory Review Period | 28 Sep, 2022 | US8071643 |
| transaction for FDA Determination of Regulatory Review Period | 28 Sep, 2022 | US8153689 |
| transaction for FDA Determination of Regulatory Review Period | 25 Sep, 2022 | US9120727 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US9120727 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8153689 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8071643 |
Nabriva's Family Patents
Nabriva drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 16.9% of its total global patent coverage. Click
below to unlock the full patent family tree.
Nabriva Drug List
Given below is the complete list of Nabriva's drugs and the patents protecting them.
1. Xenleta
Xenleta is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9120727 | Process for the preparation of pleuromutilins |
23 May, 2031
(6 years from now)
| Active |
| US8071643 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
16 Jan, 2029
(4 years from now)
| Active |
| US8153689 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
19 Mar, 2028
(3 years from now)
| Active |
| US6753445 | Pleuromutilin derivatives having antibacterial activity |
09 Jul, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xenleta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List